Hydroxychloroquine in Primary Progressive Multiple Sclerosis
Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Sponsor: University of Calgary
A PHASE2 clinical study on Multiple Sclerosis, Primary Progressive, this trial is completed. The trial is conducted by University of Calgary and has accumulated 11 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Mar 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .